Formulation Development of Sustained-Release Hydrophilic Matrix Tablets of Zileuton

1997 ◽  
Vol 2 (3) ◽  
pp. 197-204 ◽  
Author(s):  
Yihong Qiu ◽  
Ho-Wah Hui ◽  
Howard Cheskin
Keyword(s):  
Sustained Release ◽  
Matrix Tablets ◽  
Formulation Development ◽  
Hydrophilic Matrix

scholarly journals Formulation of Sustained Release Hydrophilic Matrix Tablets of Tolcapone with the Application of Sedem Diagram: Influence of Tolcapone’s Particle Size on Sustained Release

Pharmaceutics ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 674 ◽  
Author(s):  
Anna Nardi-Ricart ◽  
Isaac Nofrerias-Roig ◽  
Marc Suñé-Pou ◽  
Pilar Pérez-Lozano ◽  
Montse Miñarro-Carmona ◽  
...  
Keyword(s):  
Particle Size ◽  
Sustained Release ◽  
Potent Inhibitor ◽  
High Viscosity ◽  
Matrix Tablets ◽  
Formulation Development ◽  
Methyl Transferase ◽  
Diagram Method ◽  
Hydrophilic Matrix ◽  
Amyloid Polyneuropathy

Hydrophilic matrix tablets are a type of sustained release dosage form characterized by distributing a drug in a matrix that is usually polymeric. Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase. In recent years, it has been shown that tolcapone is a potent inhibitor of the amyloid aggregation process of the transthyretin protein, and acts by stabilizing the structure of the protein, reducing the progression of familial amyloid polyneuropathy. The main objective of this study was to obtain a sustained release tablet of tolcapone for oral administration with a preferred dosage regimen of 1 administration every 12 or 24 h and manufactured, preferably, by direct compression. The SeDeM Diagram method has been used for the formulation development of hydrophilic matrix tablets. Given the characteristics of tolcapone, the excipient selected for the formation of the polymeric matrix was a high viscosity hydroxypropylmethylcellulose (Methocel® K100M CR). A decrease in the particle size of tolcapone resulted in a slower dissolution release of the formulation when the concentration of the polymer Methocel® K100M CR was below 29%. These surprising and novel results have given rise to patent number WO/2018/019997.

Sustained-release hydrophilic matrix tablets of zileuton: formulation and in vitro/in vivo studies

1997 ◽  
Vol 45 (3) ◽  
pp. 249-256 ◽  
Author(s):  
Yihong Qiu ◽  
Howard Cheskin ◽  
Jackie Briskin ◽  
Kevin Engh
Keyword(s):  
Sustained Release ◽  
Matrix Tablets ◽  
In Vivo Studies ◽  
Hydrophilic Matrix

Formulation development and in vitro Evaluation of sustained release matrix tablets of Cefpodoxime proxetil

2021 ◽  
pp. 273-278
Author(s):  
A. Bhavani ◽  
B. Hemalatha ◽  
K. Padmalatha
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Sustained Release ◽  
Matrix Tablets ◽  
Oral Dosage ◽  
In Vitro Dissolution ◽  
Release Mechanism ◽  
Formulation Development ◽  
Cefpodoxime Proxetil

The present focus is on the development of sustained release formulations due to its inherent boons. There are several advantages of sustained release drug delivery over conventional dosage forms like improved patient compliance, reduction in fluctuation and increased safety margin of potent drug. The present study was aimed to prepare a sustained drug delivery system to design a controlled release oral dosage form of Cefpodoxime proxetil. The sustained release matrix tablets of Cefpodoxime proxetil were prepared by wet granulation and evaluated for different parameters such as weight variation, drug content, thickness, hardness, friability and In vitro release studies. The in vitro dissolution study was carried out for 12 hours using USP (Type- II) paddle apparatus in hydrochloride (0.1N) as dissolution media for first 2 hours and phosphate buffer (pH 6.8) for next 10 hours. Based on the in vitro dissolution data, formulation F8 was selected as the best formulation from Cefpodoxime proxetil formulations (F1 – F9) as the drug release was retarded up to 12 hours with 96.29 % and followed zero order release kinetics & drug release mechanism was diffusion.

scholarly journals Formulation and evaluation of sustained release diclofenac sodium matrix tablets produced using Brachystegia eurycoma gum

2020 ◽  
Vol 17 (1) ◽  
pp. 34-43
Author(s):  
Sinodukoo E. Okafo ◽  
John A. Avbunudiogba ◽  
Ejiro Ejomafuvwe
Keyword(s):  
Sustained Release ◽  
Diclofenac Sodium ◽  
Matrix Tablets ◽  
Wet Granulation ◽  
Content Uniformity ◽  
Drug Release Profile ◽  
Hydrophilic Matrix ◽  
Weight Content ◽  
The Matrix ◽  
Hardness Values

This study was carried out to evaluate sustained release diclofenac sodium matrix tablets formulated using Brachystegia eurycoma gum (BEG) as matrix polymer. BEG was isolated by acetone -precipitation of the filtrate obtained from the maceration of powdered dried seeds of Brachystegia eurycoma in distilled water. Diclofenac sodium matrix tablets were produced by non-aqueous wet granulation method using BEG as the hydrophilic matrix former. The tablets were evaluated using official and unofficial tests such as; uniformity of weight, content uniformity, dissolution test, tablets diameter, thickness, hardness and friability tests. The drug release profile of the matrix tablets were compared to that formulated using a standard matrix former, hydroxypropylmethylcellulose (HPMC). Hardness values ranged from 6.12 ± 1.80 to 9.73 ± 1.39 kgf, friability from 0.31 ± 0.00 to 1.00 ± 0.00%. The drug content ranged from 98 to 101 %. The percentage drug released from the matrix tablets after 10 h was between 71.27 and 98.73 % except for formulation BF3 that released 32.56 %. This study showed that sustained release diclofenac sodium matrix tablets were  successfully formulated using Brachystegia eurycoma gum as the matrix former and the tablets were comparable to that formulated with HPMC. Keywords: Brachystegia eurycoma gum; Diclofenac sodium; Matrix tablets; Sustained release

Effect of different polymers and their combinations on the release of metoclopramide HCl from sustained-release hydrophilic matrix tablets

2012 ◽  
Vol 18 (5) ◽  
pp. 1122-1130 ◽  
Author(s):  
Ayhan Savaşer ◽  
Çetin Taş ◽  
Ziya Bayrak ◽  
Cansel Köse Özkan ◽  
Yalçın Özkan
Keyword(s):  
Sustained Release ◽  
Matrix Tablets ◽  
Hydrophilic Matrix

scholarly journals FORMULATION DEVELOPMENT AND EVALUATION OF ALMOND GUM BASED SUSTAINED RELEASE MATRIX TABLET OF INDOMETHACIN

2018 ◽  
Vol 11 (12) ◽  
pp. 166
Author(s):  
Ruchi Sunayana S ◽  
Gowda Dv ◽  
Vishal Gupta N ◽  
Praveen Sivadasu ◽  
Manjunath M
Keyword(s):  
Sustained Release ◽  
Research Work ◽  
Morphological Characteristics ◽  
Polymeric Matrix ◽  
Matrix Tablets ◽  
In Vitro Dissolution ◽  
Matrix Tablet ◽  
Dissolution Profile ◽  
Formulation Development

Objective: The aspiration of the current research involves employing various concentrations of polymer and filler to develop indomethacin sustained release (SR) matrix tablets. The objective of this research work is to reduce dosing frequency thereby increasing patients compliance and enhanced therapeutic activity.Methods: Polymers such as Almond gum (AG), polyvinylpyrrolidone (PVP), and starch at different concentrations were used for formulating SR polymeric matrix tablets. Evaluation of pre-compression and post-compression parameters was done for both granules and formulated tablets.Results: Results obtained from pre-compression parameters and post-compression parameters suggested that all the parameters are within the prescribed limits, demonstrating that formulated granules had shown better flow properties. The morphological characteristics of the developed tablet were observed by employing scanning electron microscope where the surface of the tablet was found to be smooth from the in vitro dissolution study, combination of AG (30 mg) with PVP (30 mg), and starch used as a filler has sustained the release of drug up to 10 h.Conclusion: Therefore, developed polymeric matrix tablet exhibited enhanced potency over a conventional tablet by exhibiting an excellent dissolution profile for a period of 10 h.

Sign in / Sign up

Export Citation Format

Share Document